Table 2.
Comparison of laboratory test results among three groups
| Complication Group (n = 82) |
Diabetes Group (n = 85) |
Healthy Control Group (n = 90) |
χ2/t | P | |
|---|---|---|---|---|---|
| FPG (mmol/L) | 12.45 ± 1.29a,b | 9.39 ± 1.04b | 5.39 ± 0.87 | 936.87 | <0.001 |
| HbA1C (%) | 9.81 ± 0.17b | 9.01 ± 0.26b | 5.56 ± 0.54 | 3328.435 | <0.001 |
| TC (mmol/L) | 4.78 ± 1.17 | 4.69 ± 1.12 | 4.39 ± 1.02 | 2.988 | 0.052 |
| TG (mmol/L) | 2.38 ± 0.13b | 2.33 ± 2.08b | 1.79 ± 0.37 | 6.315 | 0.002 |
| HDL-C (mmol/L) | 1.17 ± 0.41 | 1.11 ± 0.37 | 1.03 ± 0.37 | 2.897 | 0.057 |
| LDL-C (mmol/L) | 3.02 ± 0.98 | 2.85 ± 0.91 | 2.76 ± 0.91 | 1.704 | 0.184 |
| CRP (mg/mL) | 6.78 ± 0.47a,b | 3.45 ± 0.21b | 2.49 ± 0.24 | 4071.146 | <0.001 |
| IL-6 (pg/mL) | 123.93 ± 30.93a,b | 80.99 ± 12.39b | 64.39 ± 8.73 | 209.132 | <0.001 |
| Visfatin (pg/mL) [M (QL,QU)] | 667.93 (340.83,1093.89)a,b | 372.79 (334.93,470.93)* | 358.73 (332.98,428.71) | 183.09 | <0.001 |
| JAZFl (pg/mL) [M (QL,QU)] | 122.29 (86.39,253.29)a,b | 153.39 (132.91,203.29)b | 221.92 (204.92,341.92) | 208.11 | <0.001 |
| FIns (μIU/mL) | 12.09 ± 1.21b | 12.06 ± 1.34b | 15.41 ± 2.01 | 131.363 | <0.001 |
| HOMA-IR | 6.54 ± 0.37a,b | 4.62 ± 0.36b | 3.56 ± 0.32 | 1586.769 | <0.001 |
| EAT thickness (mm) | 5.58 ± 1.23a,b | 3.58 ± 0.78b | 2.71 ± 0.54 | 233.854 | <0.001 |
| baPWV | 1698.23 ± 227.89a,b | 1607.46 ± 236.41a,b | 1320.28 ± 112.13 | 96.625 | < 0.001 |
FPG fasting plasma glucose, HbA1C hemoglobin A1C, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, CRP C-reactive protein, IL-6 interleukin-6, FIns fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance, EAT epicardial adipose tissue
acompare with Diabetes Group (P<0.05); bcompare with Healthy Control Group (P<0.05)